Cervical cancer trends in the United States: a 35-year population-based analysis.
about
Practical issues related to uterine pathology: in situ and invasive cervical glandular lesions and their benign mimics: emphasis on cytology-histology correlation and interpretive pitfallsAddressing Multilevel Barriers to Cervical Cancer Screening in Korean American Women: A Randomized Trial of a Community-Based InterventionHuman Leukocyte Antigen Class I and II Alleles and Cervical AdenocarcinomaClinical application of DNA ploidy to cervical cancer screening: A review.A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA.Human papillomavirus prevalence in a population of women living in Port-au-Prince and Leogane, HaitiDisparity in the persistence of high-risk human papillomavirus genotypes between African American and European American women of college age.Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate.The complex relationship between human papillomavirus and cervical adenocarcinoma.Improving the Utilization of Human Papillomavirus and Cervical Cytology Co-testing for Cervical Cancer Screening in an Obstetrics and Gynecology Resident Clinic.Cervical Cancer Histology, Staging and Survival before and after Implementation of Organised Cervical Screening Programme in Poland.Multispectral autofluorescence imaging for detection of cervical lesions: A preclinical study.Intimate Partner Violence and Barriers to Cervical Cancer Screening: A Gynecologic Oncology Fellow Research Network StudyTrends in Cervical Cancer Among Delivery-Related Discharges and its Impact on Maternal-Infant Birth Outcomes (United States, 1998-2009).Human Papillomavirus Laboratory Testing: the Changing ParadigmIs cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix?Results of cytology and high-risk human papillomavirus testing in females with cervical adenocarcinoma in situ.Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancerHuman papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study.Using qualitative methods to develop a contextually tailored instrument: Lessons learned.Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study.Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013.Adenocarcinoma of the cervix: should we treat it differently?Surveillance of high-grade cervical cancer precursors (CIN III/AIS) in four population-based cancer registries, United States, 2009-2012.The impact of examined lymph node count on survival in squamous cell carcinoma and adenocarcinoma of the uterine cervixRisk of persistent or recurrent cervical neoplasia in patients with 'pure' adenocarcinoma-in-situ (AIS) or mixed AIS and high-grade cervical squamous neoplasia (cervical intra-epithelial neoplasia grades 2 and 3 (CIN 2/3)): a population-based study.The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship.Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012.The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review.Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial.Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease.The Role of Laparoscopic Radical Hysterectomy in Early-Stage Adenocarcinoma of the Uterine Cervix.High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma.Association of HLA-DRB1, HLA-DQB1 Polymorphisms with HPV 16 E6 Variants among Young Cervical Cancer Patients in China.Trends in the Incidence of Cervical Cancer in Jordan, 2000-2013.Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women.Racial disparities in patient survival and tumor mutation burden, and the association between tumor mutation burden and cancer incidence rate.Cervical screening test results associated with 265 histopathologic diagnoses of cervical glandular neoplasia.Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.
P2860
Q28072431-40854D69-DB44-407D-85C3-ECE113147CDDQ29248878-88213382-9012-4AE0-8039-4731B8B6A7B6Q33775751-B3103AED-1900-48E0-A369-72B1E3680A40Q34657755-6660DE93-3B42-4A1A-A71A-85B0626AF061Q34964751-8FD208E4-5C3A-4CC2-A571-46B2BC32BE9DQ35009255-62EDD908-FB7F-42C1-A6B7-F0FF051B901AQ35078593-B2166BC0-FD77-47CB-816C-98D05EAEEC06Q35102971-DBA89DE3-B488-41D7-BD4A-AEC8515B06DEQ35762960-3A2A3A0C-0215-4914-88CD-201EF0592E70Q35954251-2CABC13C-E3F5-4FF9-AFCF-F4C384A6C1AEQ36022389-6E9D27F9-930A-47B9-B3B1-6B5E57C0BD94Q36164929-C4EBDC63-6C2B-46CC-A1EE-ED715FCFEF45Q36410398-7B547EDE-0E41-48B0-9CA3-2C41FA3A3075Q36542901-97FEBB35-5454-4BAD-810D-2A9E1BD25EE7Q36675236-70BC36E1-6077-4951-AADD-AFD36A106F08Q37025420-47827C88-4750-4893-8E21-F353CA63FDD3Q37092723-08861EEF-5FF3-49E1-83AF-65C6D1FC5C83Q37135163-3A3C840E-2394-40D7-8621-D90F7DC59D67Q37279345-55306725-2B1A-4648-A190-C12FF7877699Q37440804-2ED911E3-EB47-4E5E-B1B9-ED2967CCDCC6Q37507375-D7D6A46F-0F31-4259-B686-FA4324790BA5Q37648087-63A88F59-509B-411E-A2F7-9454FD4DCA0AQ38364617-18BA2164-3545-4DFD-A4C9-781A3904A6E4Q38648167-7C0A4B3A-2203-4815-9A66-193DD18F1ED0Q38650587-44D440D9-5C55-4100-9C50-FD03435F68A0Q38693056-83331ABA-F7D6-4952-A957-E718789593F7Q38810865-2C8A6CA8-886A-4C08-8344-C1E7831319C0Q38980532-BE357D94-5B27-4FEC-83C7-C94AC8209E1EQ39000584-C60D53AB-F58F-46BD-A016-667E58D7F507Q39132126-291314FA-E749-44C4-918D-57B98AE55D37Q39477130-E4FC5AE8-CCB8-4C02-B7EA-AD63724C96D1Q40228937-89872C83-CF46-4D21-83E7-20F6ABFA55CBQ40583368-A97B9463-AE40-472E-AE37-AFDC20037450Q41076095-42E55B21-3D9A-44E1-A50D-062E91656AE7Q41441117-A08F9C0A-A350-4F92-B3A6-D8BFBCDDBECAQ41448176-553229EE-C242-436F-AB68-553312FB7D03Q41519401-8A378670-07E9-44D0-A007-21DE2991E7BCQ42653370-03B93360-9721-4613-9987-22A61C3637D9Q46170193-3E14FCB6-9C0B-4B73-B2F8-CF418543E682Q46702041-01486FC7-FD5C-4A26-B60B-D33E568772ED
P2860
Cervical cancer trends in the United States: a 35-year population-based analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cervical cancer trends in the United States: a 35-year population-based analysis.
@ast
Cervical cancer trends in the United States: a 35-year population-based analysis.
@en
type
label
Cervical cancer trends in the United States: a 35-year population-based analysis.
@ast
Cervical cancer trends in the United States: a 35-year population-based analysis.
@en
prefLabel
Cervical cancer trends in the United States: a 35-year population-based analysis.
@ast
Cervical cancer trends in the United States: a 35-year population-based analysis.
@en
P2093
P2860
P356
P1476
Cervical cancer trends in the United States: a 35-year population-based analysis.
@en
P2093
Beth Virnig
Olusola Adegoke
Shalini Kulasingam
P2860
P304
P356
10.1089/JWH.2011.3385
P577
2012-07-20T00:00:00Z